Compugen
Market cap $191M 94.7M shares (vendor count, Nov 18, 2026) × $2.02 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-02
- Rilvegostomig HER2 readout2026Rilvegostomig HER2 readout, 2026, notable
- Rilvegostomig ARTEMIDE-01 readout2H 2026Rilvegostomig ARTEMIDE-01 readout, 2H 2026, notable
- GS-0321 Ph1 interimLate 2026 / 2027GS-0321 Ph1 interim, Late 2026 / 2027, notable
- COM701 interim1Q 2027COM701 interim, 1Q 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
Technology platforms
Unigen
AI-powered computational discovery engine for identifying novel immuno-oncology drug targets by connecting computational prediction, biological validation and clinical learning; has enabled discovery of TIGIT, PVRIG and IL-18BP as clinical-stage drug targets
Targets: TIGIT, PVRIG, IL-18BP
UnigenX
AI-powered discovery engine expansion into tumor-associated antigens for targeted immune activation modalities such as T cell engagers; designed to identify single targets and target pairs to enable more selective immune targeting of tumor cells in immuno-oncology
Capital (as filed)
- Cash
- $90.6M cash and cash equivalents · Dec 31, 2025 (20-F)
- Short-term investments
- $45.8M Dec 31, 2025
- Operating cash flow
- $7.9M annual ÷ 4, year to Dec 31, 2025 (20-F)
- As stated in coverage
- $118M cash, runway 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-10 UPDATE: Compugen (CGEN) - The Coin Is in the Air 🔒 Paid
- 2026-06-04 Compugen Ltd (CGEN) — Scientific Deep Dive for COM701, GS-0321 and the Unigen Pipeline
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on Compugen, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-04 Watch Compugen Ltd (CGEN) — Scientific Deep Dive for COM701, GS-0321 and the Unigen Pipeline Near-cash EV with partnered Phase 3 royalty and Gilead option, but the owned binary (COM701 monotherapy maintenance) rests on a post-hoc subgroup and thin single-agent data in a distrusted checkpoint class.
- 2026-11-10 Watch UPDATE: Compugen (CGEN) - The Coin Is in the Air MAIA-ovarian fully enrolled with Q1 2027 readout locked, cash floor intact at ~$85M EV, but 'totality of the data' wording raises goalpost concerns and the core tension from June remains unchanged.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
““MAIA-ovarian is now fully enrolled, and we remain on track to report results by the end of the first quarter of 2027.We are also excited to see partner AstraZeneca continue to progress rilvegostomig, with Phase 3 high-level trial results from ARTEMIDE-Biliary01 anticipated in the second half of 2027.”
matched to COM701 · interim data
-
-
-
“"Our MAIA-ovarian trial in platinum-sensitive ovarian cancer remains on track for the interim analysis with median progression-free survival data expected by the first quarter of 2027, which would mark a potential inflection point for COM701 in a patient population with a significant unmet need.”
matched to COM701 · interim data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (16)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseCompugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
- Nov 9, 2026ReleaseCompugen Reports Third Quarter 2026 Results→ BD updateSummary on the 6-K
- Nov 9, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateMAIA-ovarian is fully enrolled at n=62 and results are locked in for end of Q1 2027 — the owned binary is now a countdown, not a projection. Cash sits at $117.5M with runway into 2029 intact, and AstraZeneca's ARTEMIDE-01 Phase 2 delivered its first OS data in NSCLC.
- Nov 3, 2026ReleaseCompugen to Participate in November Investor Conferences
- Oct 26, 2026ReleaseCompugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
- Oct 6, 2026ReleaseCompugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
- Sep 22, 2026ReleaseCompugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
- Sep 10, 20266-KForeign issuer report
- Sep 8, 2026ReleaseCompugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 3, 2026ReleaseCompugen Reports Second Quarter 2026 Results
- Aug 3, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Aug 3, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 18, 2026F-3Shelf registration (foreign)
- May 18, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 2, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 2, 202620-FAnnual report (foreign)